All In Biotech

Drug Trial Radar · NCT02558452

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf

European Transplant Registry of Senior Renal Transplant Recipients Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids

Last checked: Nov 20, 2026Latest source record: Aug 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 2016

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Klemens BuddeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dr. med. univ. L. J. Lehner; Charite University, Berlin, Germany; ERA-EDTA; DESCARTES Working Group On Transplantation; European Kidney Transplant Association (EKITA)
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate long term outcomes on an observational basis.

Conditions

  • Graft Failure
  • Death
  • Acute Rejection of Renal Transplant
  • Infections
  • Bone Disease
  • Post Transplant Diabetes Mellitus
  • Quality of Life
  • HLA Antibody Production
  • Cardiovascular Risk Factors
  • Non-HLA Antibody Production

Interventions

  • Tacrolimus once daily (Advagraf)Drug

    Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient survivalTime frame: From date of transplantation until the date of death from any cause, assessed up to 10 years
  2. Renal graft survivalTime frame: From date of transplantation until the date of documented graft failure (need for permanent dialysis, explantation of the graft, retransplantation) or date of death from any cause, whichever came first, assessed up to 10 years
  3. Biopsy proven acute rejection (BPAR)Time frame: Time of transplantation to date of first BPAR and consecutive BPARs, assessed up to 10 years
  4. Development of anti-HLA antibodiesTime frame: Time of transplantation to date of first detection of any HLA antibodies, assesments are month 3 and year 1,3,5,7 and 10 in the central laboratory and all in all up to 10 years locally
  5. Renal graft function by estimated glomerular Filtration rate (eGFR) by CKD-EPI) calculationTime frame: Assesment of renal graft function over time up to 10 years or graft failure or death, whichever comes first
  6. Development of non-HLA antibodiesTime frame: Time of transplantation to date of first detection of any HLA antibodies, assesments are month 3 and year 1,3,5,7 and 10 in the central laboratory and all in all up to 10 years locally
  7. Development of donor specific antibodies (DSA)Time frame: Time of transplantation to date of first detection of any HLA antibodies, assesments are month 3 and year 1,3,5,7 and 10 in the central laboratory and all in all up to 10 years locally

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.